Omalizumab‑Igec 75 mg/0.5 mL and 150 mg/mL Suppliers & Bulk Manufacturers
Available Forms: Pre filled syringe
Available Strengths: 75 mg/0.5 mL and 150 mg/mL
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
Category: Biosimilars
Omlyclo, a biosimilar to Xolair (omalizumab), blocks immunoglobulin E (IgE), reducing allergic reactions and inflammation. It effectively treats asthma, chronic idiopathic urticaria, and other allergies. Benefits include similar efficacy, lower costs, increased access, and improved allergy management when used under medical supervision.
Product Description:
Omlyclo, a biosimilar to Xolair (omalizumab), is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality compliant with GMP and MDR standards. In the US, FDA approval involves extensive comparability data, clinical validation, and safety assessments. In the EU, CE marking certifies conformity with MDR. These biosimilars undergo validation, stability testing, and audits, with detailed documentation including biosimilarity data, clinical trial results, safety profiles, and manufacturing practices.
Omalizumab‑Igec — third party manufacturing & bulk supply
Omalizumab‑Igec 75 mg/0.5 mL and 150 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Omalizumab‑Igec listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Omalizumab‑Igec →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Tocilizumab-Bavi
Strength:
80 mg/4ml
Form: Intravenous infusion
Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).
View Details
Denosumab(Others Approved)
Strength:
60 mg, 120 mg
Form: Subcutaneous injection
Reference Brands: Xgeva(US & EU) Ospomyv, Xbryk, Merilog, Stoboclo, Zadenvi, Enwylma, Denbrayce, Izamby - biosimilar to Xgeva
View DetailsQuick Response Guaranteed | Verified Suppliers
